ICP
RXRX icon

Interchange Capital Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Interchange Capital Partners’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.3K Sell
13,439
-10,025
-43% -$33.4K 0.01% 429
2026
Q1 		$124K Buy
23,464
+3,000
+15% +$11.6K 0.04% 275
2025
Q4 		$83.7K Buy
20,464
+1,363
+7% +$6.75K 0.02% 419
2025
Q3 		$93.2K Sell
19,101
-829
-4% -$4.35K 0.02% 360
2025
Q2 		$101K Sell
19,930
-5,787
-23% -$28.4K 0.02% 277
2025
Q1 		$136K Sell
25,717
-5,106
-17% -$37.2K 0.04% 264
2024
Q4 		$202K Sell
30,823
-4,664
-13% -$31.4K 0.07% 239
2024
Q3 		$234K Buy
35,487
+907
+3% +$6.5K 0.08% 235
2024
Q2 		$268K Buy
34,580
+2,349
+7% +$20.5K 0.1% 207
2024
Q1 		$332K Buy
32,231
+9,438
+41% +$105K 0.22% 111
2023
Q4 		$224K Buy
+22,793
New +$163K 0.17% 136

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Interchange Capital Partners's RXRX Position: Q2 2026 in Review

Interchange Capital Partners reduced its Recursion Pharmaceuticals (RXRX) stake by 43% in Q2 2026, selling an estimated $33.4K and leaving 13,439 shares worth $49.3K. The position accounts for 0.01% of the portfolio, ranked #429.

Interchange Capital Partners first reported a position in RXRX in Q4 2023 and has held it in 11 quarters since. The position peaked at $332K in Q1 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Interchange Capital Partners held 13,439 shares of Recursion Pharmaceuticals worth $49.3K as of Q2 2026.
  • Interchange Capital Partners sold 10,025 Recursion Pharmaceuticals shares in Q2 2026, an estimated $33.4K.
  • Recursion Pharmaceuticals made up 0.01% of Interchange Capital Partners's portfolio in Q2 2026, its #429 holding.
  • Interchange Capital Partners first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Interchange Capital Partners's Recursion Pharmaceuticals position peaked at $332K in Q1 2024.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Interchange Capital Partners's 13F filing for Q2 2026, filed 20 Jul 2026.